Network pharmacology to unveil the mechanism of Astragali Radix in the treatment of lupus nephritis via PI3K/AKT/mTOR pathway.
TOR Serine-Threonine Kinases
/ metabolism
Proto-Oncogene Proteins c-akt
/ metabolism
Humans
Molecular Docking Simulation
Signal Transduction
/ drug effects
Phosphatidylinositol 3-Kinases
/ metabolism
Drugs, Chinese Herbal
/ pharmacology
Astragalus propinquus
/ chemistry
Network Pharmacology
Lupus Nephritis
/ drug therapy
Cell Line
Protein Interaction Maps
/ drug effects
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 10 2024
29 10 2024
Historique:
received:
17
05
2024
accepted:
25
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
We used network pharmacology, molecular docking, and in vitro experiments to explore the mechanisms of Astragali Radix in the treatment of lupus nephritis. We screened compounds and targets of Astragali Radix, as well as related genes of lupus nephritis from databases. We identified 211 common genes and 44 compounds between the herb and the disease, and constructed global, narrowed, hierarchical Compound-Target Interaction networks to illustrate the possible mechanism. We found that the PI3K/AKT/mTOR pathway is a core target gene set identified through enrichment analysis, PPI analysis and MCODE analysis. In vitro experiments showed that freeze-dried Astragali powder inhibits activation of PI3K, AKT1 and mTOR in TGF-β1 stimulated HK-2 cells. Molecular docking demonstrated that (R)-isomucronulatol, 3,9,10-trimethoxypterocarpan and astrapterocarpan exhibited promising binding affinity to PI3K, AKT, and mTOR proteins.
Identifiants
pubmed: 39472740
doi: 10.1038/s41598-024-77897-3
pii: 10.1038/s41598-024-77897-3
doi:
Substances chimiques
TOR Serine-Threonine Kinases
EC 2.7.11.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Drugs, Chinese Herbal
0
Huang Qi
922OP8YUPF
MTOR protein, human
EC 2.7.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25983Subventions
Organisme : Zhejiang Chinese Medical University Postgraduate Scientific Research Fund Project
ID : 2022YKJ07
Organisme : National Natural Science Foundation of China
ID : 82305070
Organisme : Zhejiang Province Medical and Health Technology Plan Project
ID : 2024KY1227
Organisme : Zhejiang Provincial Natural Science Foundation of China
ID : LQ23H270015
Organisme : Zhejiang Provincial Project of Traditional Chinese Medicine Science and Technology
ID : 2024ZF115
Informations de copyright
© 2024. The Author(s).
Références
Mok, C. C., Teng, Y. K. O., Saxena, R. & Tanaka, Y. Treatment of lupus nephritis: consensus, evidence and perspectives. Nat. Rev. Rheumatol. 19, 227–238 (2023).
pubmed: 36864291
doi: 10.1038/s41584-023-00925-5
Parikh, S. V., Almaani, S., Brodsky, S. & Rovin, B. H. Update on lupus nephritis: Core curriculum 2020. Am. J. Kidney Dis. 76, 265–281 (2020).
pubmed: 32220510
doi: 10.1053/j.ajkd.2019.10.017
Fanouriakis, A. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. ARD 83, 15–29 (2024).
pubmed: 37827694
Liu, L., Zhang, L. & Li, M. Application of herbal traditional Chinese medicine in the treatment of lupus nephritis. Front. Pharmacol. 13, 981063 (2022).
pubmed: 36506523
pmcid: 9729561
doi: 10.3389/fphar.2022.981063
Pharmacopoeia of the People’s Republic of China (2020 Edition), Astragali Radix. (2024).
Li & Su Jianchun Mao, & Junhua Gu. Effect of intravenous drip infusion of cyclophosphamide with high-dose Astragalus injection in treating lupus nephritis. Chin. J. Integr. Med. 272–275 (2007).
Benli Chen. The clinical study on the combined treatment of lupus nephritis Based on Chinese medicine mainly consisting of astragalus in two step sequential with western medication (Guangxi University of Chinese Medicine, 2018).
Shi, Y., Shi, X., Zhao, M., Ma, S. & Zhang, Y. Pharmacological potential of Astragali Radix for the treatment of kidney diseases. Phytomedicine 123, 155196 (2024).
pubmed: 37952410
doi: 10.1016/j.phymed.2023.155196
Barabási, A. L., Gulbahce, N. & Loscalzo, J. Network medicine: A network-based approach to human disease. Nat. Rev. Genet. 12, 56–68 (2011).
pubmed: 21164525
pmcid: 3140052
doi: 10.1038/nrg2918
Wang, X., Wang, Z. Y., Zheng, J. H. & Li, S. TCM network pharmacology: A new trend towards combining computational, experimental and clinical approaches. Chin. J. Nat. Med. 19, 1–11 (2021).
pubmed: 33516447
Zeng, P. Zhou,Hang. Homogenization of key components screening of ‘different diseases and different prescriptions’ in network pharmacology. Chin. J. Exp. Traditional Med. Formulae 28, 177–191 (2022).
Ru, J. et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform. 6, 13 (2014).
pubmed: 24735618
pmcid: 4001360
doi: 10.1186/1758-2946-6-13
Kong, X. et al. BATMAN-TCM 2.0: an enhanced integrative database for known and predicted interactions between traditional Chinese medicine ingredients and target proteins. Nucleic Acids Res. 52, D1110–D1120 (2024).
pubmed: 37904598
doi: 10.1093/nar/gkad926
Subarnas, A., Oshima, Y. & Hikino, H. Isoflavans and a pterocarpan from astragalus mongholicus. Phytochemistry 30, 2777–2780 (1991).
doi: 10.1016/0031-9422(91)85143-N
Zhang, Y. et al. Efficacy and safety of the Chinese herbal compound TJAOA101 in treating diminished ovarian reserve: A protocol for multicenter, prospective, and pre-post study. Curr. Med. Sci. 43, 284–296 (2023).
pubmed: 37059935
doi: 10.1007/s11596-023-2733-6
Song, J. Z., Yiu, H. H. W., Qiao, C. F., Han, Q. B. & Xu, H. X. Chemical comparison and classification of Radix Astragali by determination of isoflavonoids and astragalosides. J. Pharm. Biomed. Anal. 47, 399–406 (2008).
pubmed: 18272311
doi: 10.1016/j.jpba.2007.12.036
Yu, D., Duan, Y., Bao, Y., Wei, C. & An, L. Isoflavonoids from Astragalus mongholicus protect PC12 cells from toxicity induced by L-glutamate. J. Ethnopharmacol. 98, 89–94 (2005).
pubmed: 15763368
doi: 10.1016/j.jep.2004.12.027
Ohkawara, S., Okuma, Y., Uehara, T., Yamagishi, T. & Nomura, Y. Astrapterocarpan isolated from astragalus membranaceus inhibits proliferation of vascular smooth muscle cells. Eur. J. Pharmacol. 525, 41–47 (2005).
pubmed: 16297381
doi: 10.1016/j.ejphar.2005.08.063
Stelzer, G. et al. The geneCards suite: From gene data mining to disease genome sequence analyses. CP Bioinf. 54, (2016).
Amberger, J. S., Bocchini, C. A., Scott, A. F. & Hamosh, A. OMIM.org: leveraging knowledge across phenotype-gene relationships. Nucleic Acids Res. 47, D1038–D1043 (2019).
pubmed: 30445645
doi: 10.1093/nar/gky1151
Piñero, J. et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 48, D845–D855 (2020).
pubmed: 31680165
Ashburner, M. et al. Gene ontology: tool for the unification of biology. Nat. Genet. 25, 25–29 (2000).
pubmed: 10802651
pmcid: 3037419
doi: 10.1038/75556
Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30 (2000).
pubmed: 10592173
pmcid: 102409
doi: 10.1093/nar/28.1.27
Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44, D457–462 (2016).
pubmed: 26476454
doi: 10.1093/nar/gkv1070
Milacic, M. et al. The reactome pathway knowledgebase 2024. Nucleic Acids Res. 52, D672–D678 (2024).
pubmed: 37941124
doi: 10.1093/nar/gkad1025
Wu, S. et al. Jieduquyuzishen prescription attenuates renal fibrosis in MRL/lpr mice via inhibiting EMT and TGF-β1/Smad2/3 pathway. Evid. Based Complement. Alternat. Med. 4987323 (2022).
Yang, J. & Li, S. Molecular mechanism of hedyotis diffusae herba in the treatment of lupus nephritis based on network pharmacology. Front. Pharmacol. 14, 1118804 (2023).
pubmed: 37361229
pmcid: 10285311
doi: 10.3389/fphar.2023.1118804
Ding, T. et al. Luteolin attenuates lupus nephritis by regulating macrophage oxidative stress via HIF-1α pathway. Eur. J. Pharmacol. 953, 175823 (2023).
pubmed: 37263402
doi: 10.1016/j.ejphar.2023.175823
Bilanges, B., Posor, Y. & Vanhaesebroeck, B. PI3K isoforms in cell signalling and vesicle trafficking. Nat. Rev. Mol. Cell. Biol. 20, 515–534 (2019).
pubmed: 31110302
doi: 10.1038/s41580-019-0129-z
Yu, J. S. L. & Cui, W. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. Development 143, 3050–3060 (2016).
pubmed: 27578176
doi: 10.1242/dev.137075
Beşliu, A. N. et al. PI3K/Akt signaling in peripheral T lymphocytes from systemic lupus erythematosus patients. Roum Arch. Microbiol. Immunol. 68, 69–79 (2009).
pubmed: 20361524
Stylianou, K. et al. The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin. Nephrol. Dial. Transplant. 26, 498–508 (2011).
doi: 10.1093/ndt/gfq496
Mao, Z. et al. Renal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis. Rheumatology 61, 3830–3840 (2022).
pubmed: 35040950
pmcid: 9608003
doi: 10.1093/rheumatology/keac037
Nowling, T. K. Mesangial cells in lupus nephritis. Curr. Rheumatol. Rep. 23, 1–10 (2021).
doi: 10.1007/s11926-021-01048-0
Cristofano, A. D. et al. Impaired fas response and autoimmunity in Pten+/– mice. Science 285, 2122–2125 (1999).
pubmed: 10497129
doi: 10.1126/science.285.5436.2122
Wang, B., Luo, Y., Zhou, X. & Li, R. Trifluoperazine induces apoptosis through the upregulation of Bax/Bcl–2 and downregulated phosphorylation of AKT in mesangial cells and improves renal function in lupus nephritis mice. Int. J. Mol. Med. 41, 3278–3286 (2018).
pubmed: 29568865
pmcid: 5881739
Mohan, C., Zhang, T. & Putterman, C. Pathogenic cellular and molecular mediators in lupus nephritis. Nat. Rev. Nephrol. 19, 491–508 (2023).
pubmed: 37225921
doi: 10.1038/s41581-023-00722-z
Sayers, E. W. et al. Database resources of the national center for biotechnology information. Nucleic Acids Res. 50, D20–D26 (2022).
pubmed: 34850941
doi: 10.1093/nar/gkab1112
Zhou, X. et al. Astragaloside IV from astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting inflammation via TLR4/NF-кB in vivo and in vitro. Int. Immunopharmacol. 42, 18–24 (2017).
pubmed: 27855303
doi: 10.1016/j.intimp.2016.11.006
Zhou, W. et al. Network pharmacology to unveil the mechanism of Moluodan in the treatment of chronic atrophic gastritis. Phytomedicine 95, 153837 (2022).
pubmed: 34883416
doi: 10.1016/j.phymed.2021.153837
Mochida, K., Koda, S., Inoue, K. & Nishii, R. Statistical and machine learning approaches to predict gene regulatory networks from transcriptome datasets. Front. Plant. Sci. 9, (2018).
Nadeem, U. et al. Using advanced bioinformatics tools to identify novel therapeutic candidates for age-related macular degeneration. Transl Vis. Sci. Technol. 11, 10 (2022).
pubmed: 35972434
pmcid: 9396676
doi: 10.1167/tvst.11.8.10
Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
pubmed: 14597658
doi: 10.1101/gr.1239303
Szklarczyk, D. et al. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638–D646 (2023).
pubmed: 36370105
doi: 10.1093/nar/gkac1000
Nogales, C. et al. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol. Sci. 43, 136–150 (2022).
pubmed: 34895945
doi: 10.1016/j.tips.2021.11.004
Bader, G. D. & Hogue, C. W. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 4, 2 (2003).
doi: 10.1186/1471-2105-4-2
Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012).
pubmed: 22930834
pmcid: 5554542
doi: 10.1038/nmeth.2089
O’Boyle, N. M. et al. Open Babel: An open chemical toolbox. J. Cheminform. 3, 33 (2011).
pubmed: 21982300
pmcid: 3198950
doi: 10.1186/1758-2946-3-33
Burley, S. K. et al. RCSB Protein Data Bank (RCSB.org): delivery of experimentally-determined PDB structures alongside one million computed structure models of proteins from artificial intelligence/machine learning. Nucleic Acids Res. 51, D488–D508 (2023).
pubmed: 36420884
doi: 10.1093/nar/gkac1077
Varadi, M. et al. AlphaFold protein structure database in 2024: providing structure coverage for over 214 million protein sequences. Nucleic Acids Res. 52, D368–D375 (2024).
pubmed: 37933859
doi: 10.1093/nar/gkad1011
Valdés-Tresanco, M. S., Valdés-Tresanco, M. E., Valiente, P. A. & Moreno, E. AMDock: a versatile graphical tool for assisting molecular docking with Autodock Vina and Autodock4. Biol. Direct. 15, 12 (2020).
pubmed: 32938494
pmcid: 7493944
doi: 10.1186/s13062-020-00267-2